A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

PURPOSE: Vandetanib, a tyrosine kinase inhibitor of KDR (VEGFR2), EGFR, and RET, may enhance sensitivity to chemotherapy and radiation. We conducted a randomized, noncomparative, phase II study of radiation (RT) and temozolomide with or without vandetanib in patients with newly diagnosed glioblastom...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Lee, Eudocia Q., Kaley, Thomas J., Duda, Dan G., Schiff, David, Lassman, Andrew B., Wong, Eric T., Mikkelsen, Tom, Purow, Benjamin W., Muzikansky, Alona, Ancukiewicz, Marek, Huse, Jason T., Ramkissoon, Shakti, Drappatz, Jan, Norden, Andrew D., Beroukhim, Rameen, Weiss, Stephanie E., Alexander, Brian M., McCluskey, Christine S., Gerard, Mary, Smith, Katrina H., Jain, Rakesh K., Batchelor, Tracy T., Ligon, Keith L., Wen, Patrick Y.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4790106/
https://ncbi.nlm.nih.gov/pubmed/25910950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3220
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller